ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, recent research showed that the active uptake of imatinib into cells was mediated mainly by the SLC22A4 transporter, and the different genotypes of the promoter of SLC22A4 were significantly associated with the imatinib response in CML.27, 28, 29 In this work, we attempt to provide a new therapeutic target for CML with BCR-ABL-independent imatinib resistance.